What is Beijing Biotechnology?
Beijing Institute of Biological Products, founded in 1956, is the only original research unit in China that has mastered the quality control technology for the production of lethal pathogen toxin preparations, and is also the first unit to carry out the production of sterile preparations. Over time, Beijing Biotech has gradually grown into one of the well-known companies in the field of domestic biological vaccines. Chairman Shu Guangyi founded the non-profit research institution Beijing Wuqiong Biotechnology Research Institute in 2016, dedicated to developing vaccines.
Why has no one beaten Beijing Biology?
Recently, during the COVID-19 epidemic, the inactivated vaccine developed by Beijing Biotech has attracted widespread attention. However, why Beijing Biotechnology’s vaccine has been “lack of interest” for a long time is worthy of our further investigation. The following is an analysis from four aspects: product, market, brand, and price.
Products
One of the main reasons why Beijing Biovaccine has been \”lack of interest\” for a long time is that their product categories are single, mainly producing inactivated vaccines, such as freeze-dried human hepatitis B vaccine, meningitis vaccine, chickenpox vaccine, etc. Compared with other vaccine manufacturers (such as Sinopharm and Changchun Changsheng), Beijing Biological\’s product line has not formed a complete product chain and lacks core products that can be followed up in the high-end vaccine field.
Market
In terms of market, Beijing Biotech’s business is mainly concentrated in China’s domestic market. The vaccines covered by its products mainly include hepatitis B vaccine, meningitis vaccine and rabies vaccine. However, due to the number of varieties and pressure from competitors, the company’s domestic products are The COVID-19 vaccine market still faces great competitive pressure. Due to various reasons, the company did not carry out corresponding research and development work until the recent COVID-19 outbreak. Therefore, compared with biologic manufacturers that already had a research and development foundation at that time, the production line was insufficient.
Brand
Beijing Biotech faces fierce competition in the domestic vaccine market, and the industry generally believes that the vaccines produced by Beijing Biotech enjoy a high reputation in contributing to domestic immune prevention. However, in terms of brand promotion and product promotion, due to the lack of a pyramid-shaped product line, the company lacks \”blockbuster\” products, making it appear low-key in the market.
Price
The price of Beijing Biotech\’s vaccines is relatively low, which has also become a drawback for the company. Although the quality of Beijing Biotech\’s vaccines is excellent, it has not been able to form a huge advantage in the same industry because the price is not conspicuous enough. In addition, due to the particularity of the vaccine market, buying cheaper products will often prove to be a less wise choice for customers who focus on reputation and quality. It can be seen that in the vaccine market, the impact of quality, reputation, price and brand cannot be ignored.
Summary
Beijing Biotech has various problems in the current vaccine market, which has caused it to be \”lack of interest\” for a long time and fall into a long-term depression. However, with the outbreak of the new crown epidemic, the Institute of Biological Products has begun to develop a new crown vaccine, and the company\’s future direction may change. Although the particularity of the vaccine market will affect its market performance, the key lies in whether it can early realize the opportunities and challenges brought by market changes and further enhance its products, brands and markets.competitiveness to achieve sustainable and rapid development.
